FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012524210> ?p ?o ?g. }

• W2012524210 endingPage "7" @default.
• W2012524210 startingPage "1" @default.
• W2012524210 abstract "Several chemotherapy studies have suggested that continuous infusion of 5-fluorouracil (5-FU) is more effective than bolus 5-FU. In addition, 5-FU and cis-Diamminedichloroplatinum-II (cisplatin) in combination have been shown to have synergistic cytotoxicity against several human neoplasms. In this study, the authors evaluated the efficacy and toxicity of continuous infusion of 5-FU and low dose cisplatin infusion (FP therapy) in the treatment of advanced and recurrent gastric adenocarcinoma. The relationship between the response to FP therapy and several factors was also examined.A total of 26 patients fulfilling standard eligibility criteria were enrolled in the trial. FP therapy consisted of 5-FU (350 mg/m2/day every day by continuous infusion) and cisplatin (7.5 mg/m2/day in 100 mL of normal saline infused over 1 hour on Days 1-5 every week) for 4 weeks.A complete response was observed in 2 cases and a partial response in 11 cases, for an overall response rate of 50%. Patients with good performance status (PS) (0-1) and differentiated histologic type showed higher response rates (50.0% and 63.6%, respectively) than patients with poor PS (2 or 3) and undifferentiated histologic type (28.6% and 35.3%, respectively), although there were no significant differences. Patients with low serum levels of immunosuppressive acidic protein (IAP) showed a significantly higher response rate (71.4%) than those with high IAP levels (0%). Toxic effects included leukopenia, thrombocytopenia, nausea, and vomiting; these were not life-threatening and did not require treatment interruption.FP therapy is a promising regimen for patients with advanced and recurrent gastric adenocarcinoma. Serum levels of IAP may predict chemosensitivity." @default.
• W2012524210 created "2016-06-24" @default.
• W2012524210 creator A5007644928 @default.
• W2012524210 creator A5012583818 @default.
• W2012524210 creator A5017230904 @default.
• W2012524210 creator A5018984030 @default.
• W2012524210 creator A5023659863 @default.
• W2012524210 creator A5032693016 @default.
• W2012524210 creator A5032709542 @default.
• W2012524210 creator A5034848801 @default.
• W2012524210 creator A5047939598 @default.
• W2012524210 creator A5057051718 @default.
• W2012524210 creator A5074337807 @default.
• W2012524210 date "1997-07-01" @default.
• W2012524210 modified "2023-10-16" @default.
• W2012524210 title "Continuous infusion of 5‐fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma" @default.
• W2012524210 cites W1863898801 @default.
• W2012524210 cites W1883602322 @default.
• W2012524210 cites W1889467937 @default.
• W2012524210 cites W1902766545 @default.
• W2012524210 cites W1958288236 @default.
• W2012524210 cites W1972702230 @default.
• W2012524210 cites W1995140962 @default.
• W2012524210 cites W1996197523 @default.
• W2012524210 cites W1996285570 @default.
• W2012524210 cites W2018975005 @default.
• W2012524210 cites W2020824048 @default.
• W2012524210 cites W2033166317 @default.
• W2012524210 cites W2036409540 @default.
• W2012524210 cites W2036745924 @default.
• W2012524210 cites W2044228838 @default.
• W2012524210 cites W2049333732 @default.
• W2012524210 cites W2053995869 @default.
• W2012524210 cites W2060005073 @default.
• W2012524210 cites W2066312401 @default.
• W2012524210 cites W2077009432 @default.
• W2012524210 cites W2080768476 @default.
• W2012524210 cites W2086855064 @default.
• W2012524210 cites W2094759106 @default.
• W2012524210 cites W2099273115 @default.
• W2012524210 cites W2108779475 @default.
• W2012524210 cites W2109388689 @default.
• W2012524210 cites W2111718148 @default.
• W2012524210 cites W2112772700 @default.
• W2012524210 cites W2136011315 @default.
• W2012524210 cites W2146505874 @default.
• W2012524210 cites W2161174144 @default.
• W2012524210 cites W2167805334 @default.
• W2012524210 cites W2228615843 @default.
• W2012524210 cites W2264388209 @default.
• W2012524210 cites W2288788326 @default.
• W2012524210 cites W2311750399 @default.
• W2012524210 cites W4250434184 @default.
• W2012524210 doi "https://doi.org/10.1002/(sici)1097-0142(19970701)80:1<1::aid-cncr1>3.0.co;2-#" @default.
• W2012524210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9210702" @default.
• W2012524210 hasPublicationYear "1997" @default.
• W2012524210 type Work @default.
• W2012524210 sameAs 2012524210 @default.
• W2012524210 citedByCount "36" @default.
• W2012524210 countsByYear W20125242102012 @default.
• W2012524210 countsByYear W20125242102013 @default.
• W2012524210 crossrefType "journal-article" @default.
• W2012524210 hasAuthorship W2012524210A5007644928 @default.
• W2012524210 hasAuthorship W2012524210A5012583818 @default.
• W2012524210 hasAuthorship W2012524210A5017230904 @default.
• W2012524210 hasAuthorship W2012524210A5018984030 @default.
• W2012524210 hasAuthorship W2012524210A5023659863 @default.
• W2012524210 hasAuthorship W2012524210A5032693016 @default.
• W2012524210 hasAuthorship W2012524210A5032709542 @default.
• W2012524210 hasAuthorship W2012524210A5034848801 @default.
• W2012524210 hasAuthorship W2012524210A5047939598 @default.
• W2012524210 hasAuthorship W2012524210A5057051718 @default.
• W2012524210 hasAuthorship W2012524210A5074337807 @default.
• W2012524210 hasConcept C121608353 @default.
• W2012524210 hasConcept C126322002 @default.
• W2012524210 hasConcept C2776694085 @default.
• W2012524210 hasConcept C2778239845 @default.
• W2012524210 hasConcept C2780456651 @default.
• W2012524210 hasConcept C2780580376 @default.
• W2012524210 hasConcept C2780852908 @default.
• W2012524210 hasConcept C2780873365 @default.
• W2012524210 hasConcept C2781182431 @default.
• W2012524210 hasConcept C29730261 @default.
• W2012524210 hasConcept C3018112808 @default.
• W2012524210 hasConcept C43376680 @default.
• W2012524210 hasConcept C71924100 @default.
• W2012524210 hasConcept C90924648 @default.
• W2012524210 hasConceptScore W2012524210C121608353 @default.
• W2012524210 hasConceptScore W2012524210C126322002 @default.
• W2012524210 hasConceptScore W2012524210C2776694085 @default.
• W2012524210 hasConceptScore W2012524210C2778239845 @default.
• W2012524210 hasConceptScore W2012524210C2780456651 @default.
• W2012524210 hasConceptScore W2012524210C2780580376 @default.
• W2012524210 hasConceptScore W2012524210C2780852908 @default.
• W2012524210 hasConceptScore W2012524210C2780873365 @default.
• W2012524210 hasConceptScore W2012524210C2781182431 @default.
• W2012524210 hasConceptScore W2012524210C29730261 @default.
• W2012524210 hasConceptScore W2012524210C3018112808 @default.

• next